Download presentation

Published byAntony Freeman Modified over 3 years ago

1
**LECTURE 3 – June 9 2006 Cohort Studies, Selection Bias Survival analysis**

Dr. Dick Menzies

2
**Cohort Studies – General**

Prospective study: Incidence of new disease in persons who start without disease. Follow-up period – weeks, months, years One or more diseases can be measured Measure exposures – at start or ongoing. Can measure multiple exposures Compare incidence in exposed vs unexposed groups within population – per unit of time

3
**Advantages of cohort over case-control or cross-sectional designs**

KEY – exposure measurement is made before disease occurs Exposure more accurate – prospective, and often repeated Eliminates bias in measurement of exposures: Recall bias of patients, or observer bias in exposure assessment - with knowledge of disease status.

4
**Experimental vs cohort studies**

Expt studies are a form of cohort study Same - Persons are free of disease at outset But - Exposure is RANDOMLY ASSIGNED to some/not others Same - Measure outcomes after exposure Cohort study – exposures NOT assigned, but occur naturally, or are chosen purposely by subjects, or by their MD’s, etc

5
**Advantages of cohort studies over experimental**

Ideal to study natural history, course of disease, prognostic factors. Etiologic research for exposures that can not be given experimentally, for ethical reasons Smoking, asbestos, air pollution Interventions not feasible for randomization Diagnostic tests, complex care management Some outcomes not well measured in trials: Compliance by patients and MD’s,

6
**Advantages of cohort studies over experimental**

Total population studied. Children, elderly, pregnancy, mentally incompetent, Full spectrum of illness From patients in ICU to minimal forms of disease Often excluded in RCT – esp Pharma trials Findings more likely to be applicable in real world Adverse events often more accurately measured Population based estimates of exposure effects BUT you MUST include the full spectrum of patients as possible (No exclusions in observational studies)

7
Disadvantages Selection bias – Persons who get exposed not same as unexposed Surgery – who is ‘operable’ vs ‘inoperable’ Exposures that seem same, are not Potential bias in measuring Drop-outs – reduce power, may bias (a lot) Outcome assessment can be biased

8
Cohort Designs Prospective: Subjects without disease followed to determine incidence of diseases Exposures measured at baseline, and/or concurrently. Disease – measured during follow-up Retrospective: Subjects first identified based on past Exposures (Hiroshima survivors, work-force) Outcomes may then be ascertained directly, or also have already occurred Key – exposure well defined, AND occurred well before disease (useful for diseases like cancer)

9
**Cohort Populations General populations – no special exposures**

Framingham study – a true general population All persons in the community invited Proxy general Pop’n - Nurses, Military, Company Exposures studied are those of general pop’n. Diet, exercise, smoking, alcohol Exposure defined cohort Work-force to study occupational exposures Group of patients who received certain therapy

10
**Cohorts of patients Clinical cohorts – patients with a given condition**

Case series can be form of cohort study But – must have differences in ‘exposure’ Different types, severity, causes Potential problems in cohort studies with patients: Referral bias – only sickest, rarest, Lead-time bias – better facilities = earlier Dx Multi-serial cohorts – Cohort starts with all diabetics in 2004 New, and old = very different patients

11
**Open versus Closed Cohorts**

An open cohort – or dynamic cohort - is one where people can enter or leave Examples: A workforce study that is ongoing A city or other geographic location A closed cohort is where all persons in the cohort are defined at entry. No one enters, members can only exit. Eg. McGill medical school class of 2004

12
Selection Bias Definition – selection bias occurs when there is a distortion in the estimate of effect (association) because the study or sample population is not truly representative of the underlying population in terms of the distribution of exposures and/or outcomes. Other terms: referral bias, volunteer bias, healthy worker effect, susceptibility bias, drop-out bias How/where in a study can this occur?

13
**GROUPS LOSSES REASONS FOR LOSSES INTENDED POPULATION AVAILABLE GROUP**

CANDIDATE GROUP ELIGIBLE GROUP QUALIFIED GROUP ADMITTED GROUP NOT AVAILABLE CANDIDATES ELIGIBLE EXCLUDED NON- RECEPTIVE Treated at other hospitals or by other doctors Not identified or accessible Did not fulfill diagnostic criteria Superimposed condition of severity, co-morbidity, co-medication, or non-compliance Refused participation or acceptance of assigned maneuver Figure Diagram showing successive transfers from the intended population to the group admitted to a study of therapy

14
**Obtaining a representative sample**

In a representative sample we hope for a sample that shows us the true underlying distribution of exposure and disease: Truth – distribution of exposure and disease in source population Exposed Not Exposed Diseased A B Not Diseased C D Odds Ratio = (A/B) / (C/D) = A x D B x C

15
**Un-biased Sampling x 1 = Truth! Odds Ratio = (P1 x P4) x (A x D)**

Exposed Not Exposed Diseased P1A P2B Not Diseased P3C P4D Odds Ratio = (P1 x P4) x (A x D) (P2 x P3) (B x C) IF (P1 x P4) THEN OR = (A x D) (P2 x P3) (B x C) x 1 = Truth!

16
**Biased Sampling If sample all of A (P1=1) but only half of B (P2 =0.5)**

Exposed Not Exposed Diseased P1A P2B Not Diseased P3C P4D If sample all of A (P1=1) but only half of B (P2 =0.5) And 1/3 of C and D (P3=0.33, P4=0.33) Odds Ratio = (P1 x P4) = (1x.33) = 2 x (A x D) (P2 x P3) = (.5X.33) (B x C) IF (P1 x P4)=2 THEN ORestimated = 2X ORTrue (P2 x P3)

17
**Example – Biased sampling**

We are planning a case control study of spicy foods and peptic ulcer disease Cases = endoscopy proven peptic ulcer disease Controls = elective inguinal hernia repair at the same hospital The truth: no relationship i.e. the odds ratio = 1 The problem – physician at this hospital strongly believe spicy foods is an important risk factor for peptic ulcer disease. Therefore they tend to refer patients for endoscopy more often if they had a diet of spicy foods

18
**Biased sampling (cont’d)**

TRUTH: Spicy Foods No Spicy Foods Odds Truth Cases 25 75 25/75 Controls Total 50 150 1.0 Biased sample 37.5 25/37.5 112.5 2.0

19
**Example: biased sampling**

So, 100% of patients with peptic ulcer disease AND history of spicy foods have endoscopy But only half of those with peptic ulcer, but WITHOUT history of spicy food are in fact diagnosed – (they do not have endoscopy, so they are missed) Estimated association will be twice what is correct.

20
**To achieve Un-biased Sampling**

To achieve un-biased sampling the easiest is: P1= P2=P3=P4 This means the proportion sampled from each group is the same, i.e., 10% are sampled from each of the groups However if P1 is higher than P2 this can be okay as long as P4 is also increased more than P3

21
**Volunteer Bias Participants in a study are different from refuseniks**

Mortality of non-participants in the Framingham study Subjects with exposure and the outcome are more (or less) likely to participate Eg HIV infection and homosexuality – in Africa Disease and occupational exposures, particularly for self-reported exposures, and compensable illnesses.

22
Susceptibility bias Persons allocated to one form of treatment, or who who self-select to certain exposures are more, or less susceptible to develop health outcomes of interest. Eg Cancer patients who have surgery vs medical or radiotherapy only. Surgical patients often appear to do better.

23
**Healthy worker effect An important bias – found in work-force studies**

Reflects medical screening (military, mining) Or, physical requirements of job Results in better health status initially than general population, or certain control pop’n Strongly affects results in cross-sectional studies Reduces risk or delays occurrence of health outcomes of interest. Also occurs in smokers “healthy smoker effect” Lung function in adolescent smokers > non-smokers

24
**Example of healthy smoker effect**

25
**Selection Bias in Cohort Studies – Dropouts**

Losses to follow up occur in all cohort studies Reduce power, and dilute results Problematic if more drop-outs in one exposure group REALLY important if drop-out is due to development of disease

26
**Selection Bias in Cohort Studies – Dropouts**

Example: study of incidence of diabetes in obese persons. Truth: IRR = 3.0 Losses – 33% in diabetes/obesity group (death/other) 5% losses in all other groups (P1 x P4) does not = 1 (P2 x P3)

27
**Selection Bias from Dropouts - Example**

At onset Dropped No DM Out Diabetes Detected at end with diabetes Obese 227 10 9 18 Not Obese 773 35 3 30 Incidence (biased): In obese – 18/208 = 8.7% In non-obese – 30/735 = 4.1% Biased incidence rate ratio – 8.7%/4.1% = 2.1

28
**Drop-outs from a work-force - impact**

An occupational exposure causes health effects quickly in a susceptible sub-group. They leave the work-force (quit) quickly. Examples: Allergy to lab animals in researchers Asthma in Grain workers Cross-sectional studies – no susceptibles left Cohorts – Can miss when setting up cohort. Outcomes occur in small number of new workers (power problem)

29
**Controlling Selection Bias**

Control in design - Most important is prevention Recruitment – high % in all groups Same %recruitment in exposed/not exposed Close follow-up to prevent dropouts Assess in analysis Compare participants to non-participants Sub-groups of non-participant Compare dropouts with those who remained Sensitivity analysis – best case/ worst case to assess impact of selection biases

30
**Cohort Studies – Exposure Assessments**

Prospective - Measure one or more exposures at start Specific: cholesterol, obesity, smoking, blood pressure. Proxies: occupation, housing Measure once, or repeatedly to account for changes in exposure over time (obesity, smoking, BP). Retrospective Exposure based upon past events These are rarely quantified Proxies used (job description, distance from blast) Sometimes records (transfusions, dust levels)

31
**Pitfalls in exposure assessments**

Observer bias – disease ascertained at same time Blind observers to study hypothesis Standardized protocols Are all exposures the same? Complications of pleural tap at MGH/RVH >> MCI Did you forget something? Hard to go back to the start of cohort Measure everything, freeze the rest Add measures as new things reported

32
**Cohort Studies – Outcome Assessments**

Baseline – ensure cohort members free of disease. Easy if prospective, harder if retrospective Outcomes measured periodically Through questionnaire, exam, labs (direct) Through health service utilization (databases) Through vital statistics (databases) Case definition key for outcome assessments Diagnosis of milder disease common problem

33
**Pitfalls in outcome assessments**

Ascertainment bias – if patients with Factor X are more likely to have testing to detect outcome. Standardized protocols, blinding to exposures Observer bias – patients with Factor X more likely to be diagnosed with outcome of interest Common with more subjective tests – eg CXR Solution – independent reviewers, blinded to exposure status (Factor X) Lead time bias – earlier diagnosis makes survival look better

34
**Lead-time bias - example**

35
**Cohort Studies – Measures of Incidence**

Incidence rate (simplest) = number developing disease Total number who entered cohort per unit of time Cumulative incidence = Over total follow-up period

36
**Measuring Incidence in Cohort Studies How to handle drop outs etc..?**

Drop-outs from loss to follow-up, death other causes, or withdraw consent are common Up to 50% in long term cohorts Include or exclude from analysis? Simple incidence measures - excludes Need to allow variable length of follow up And count people who enter after the first year

37
**Incidence Density (ID)**

Counts person-time (person-years/months) Starts count when person enters cohort Each year of follow-up added up Patient Exposed Enter in year Stop in Year Years of FU Disease occurrence 1 YES 3 2 NO 12 10 8 4 11 ID in Exposed = 1 event in 12 person years ID in Unexposed = 1 event in 18 person years

38
**Cohort studies – Measure of Association: Risk Ratios, or Incidence rate ratios**

Summary measure of association in Cohort Studies Formula for Incidence rate ratio (IRR) = Incidence of disease in persons with exposure Incidence of disease in persons without exposure Ndisease/Nexposed per unit time Ndisease/Nunexposed per unit time * Note – in IRR there is no unit of time. This assumes the amount of time was similar for those with and without disease and those exposed and unexposed or

39
**Calculation of Risk Ratio - example**

Cohort at inception: 1,000 people without diabetes Prevalence of obesity at inception = 22.7% Outcome: Incidence of diabetes in a population Exposure - obesity at inception of cohort Follow-up - six years Overall incidence of diabetes = 1% per year Cumulative Incidence = 6% Risk = cumulative incidence

40
**Risk Ratio Calculation - Example**

Number with exposure Developed Diabetes Cumulative Incidence rate Obese 227 27 27/227 Non Obese 773 33 33/773 Total 1,000 60 Ratio of Incidence = risk ratio = 27/227 / 33/773 = 12 / 4 =

41
**Incidence Density Ratio**

Patient Exposed Follow up Years Disease 1 YES 2 NO 10 3 8 4 Incidence rate ratio = (1/2) / (1/2) = 1 Density method = (0/2 years) + (1/10 years) (0/8 years) + (1/10 years) Incidence density ratio = (1/12) (1/18) = 1.5

42
**Incidence Rate Difference**

A patient asks “How much will my risk of heart attack go down if I take this new drug (B), instead of old one (A)?” Answer using incidence rate difference Incidence with Drug A - Incidence with Drug B = 0.5%/year – 0.3%/year = 0.2%/year, or, a 40% reduction Same answer using Incidence rate ratio: = Incidence with Drug B = 0.3% = 0.6, or, a 40% reduction Incidence with Drug A %

43
Attributable risk “How many lung cancers are due to air pollution in Montreal?” Same as “What is attributable risk?” Attributable risk = IRR x Prevalence of exposure Increases with higher IRR Or if exposure more common Diabetes vs Silicosis and TB Diabetes: IRR = 3.5, Prevalence = 3% Silicosis: IRR = 12, Prevalence = 0.1% Attrib risk for Diabetes >> than for Silicosis

44
**Cohort Studies – Survival Analysis**

Analysis of time to event Accounts for variable length of follow up. Advantage if time to event affected by exposure. Can find important differences in treatments even overall survival same: Cancer treatment A increases survival at two years But five year mortality is same as treatment B. Treatment A - preferred by most patients!

45
**Important differences found using Survival analysis**

46
**Types of Survival Analysis**

Simplest – Direct Kaplan-Meier – still pretty simple. Calculates cumulative proportion free of outcome (survived) at each point in time when that outcome occurs. People who drop out or die of other causes are ‘censored’. At each point numerator is all who have developed disease, while denominator is all without outcome in the interval just before Cox regression analysis – multivariate analysis with same basic principles

47
**Kaplan Meier survival analysis - example**

Time Number at start During interval Surviving at end Proportion surviving Drop-outs Deaths Interval Cumulative 100 1.0 3 months 10 90 6 months 70 0.88 10 months 60 0.86 0.75 12 months 40 0.8 0.6 18 months 30 Notes: Intervals are variable – defined by when subjects die Proportion surviving interval – excludes drop-outs during the interval (censored)

48
**Kaplan Meier survival analysis - example**

49
**Example of Kaplan-Meier analysis: General Hospital Ventilation and time to TST conversion**

50
**Selection Bias – Berkson’s**

This is described in case control studies in hospitalized patients First described on mathmatical basis. Probability Hospitalization if Factor Z = 0.1 Probability Hospitalization if Factor Y = 0.05 Probability Hospitalization if both = higher These two independent conditions will appear to be associated – but may not be. In practice it is common that patients with 2 or more conditions ARE more likely hospitalized (eg CHF and pneumonia) so in hospital based Case-control study they appear to be strongly associated. Fundamental problem is the same. P1 does not equal P2 does not equal P3 does not equal P4

Similar presentations

OK

From Clinical Observations to Research Hierarchy of Study Designs Dr. Dick Menzies June th, 2006.

From Clinical Observations to Research Hierarchy of Study Designs Dr. Dick Menzies June th, 2006.

© 2018 SlidePlayer.com Inc.

All rights reserved.

Ads by Google

Download ppt on oxidation and reduction practice Ppt on travel and tourism in rajasthan Ppt on cola drinks and their ill effects Ppt on ten figures of speech Animated ppt on magnetism experiments Ppt on case study of drought in india Ppt on limitation act india Ppt on basic etiquette and manners Ppt on crop production management Ppt on face recognition technology using matlab